These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15581455)

  • 21. Defining the challenges of familial hypercholesterolemia screening: introduction.
    Hopkins PN
    J Clin Lipidol; 2010; 4(5):342-5. PubMed ID: 21122675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAS Consensus Panel statement on homozygous FH.
    Stock J
    Atherosclerosis; 2015 Sep; 242(1):323-6. PubMed ID: 26247683
    [No Abstract]   [Full Text] [Related]  

  • 23. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
    Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
    Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A conversation with Helen Hobbs.
    Hobbs H; Neill US
    J Clin Invest; 2015 Oct; 125(10):3725-6. PubMed ID: 26426073
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic heterogeneity of autosomal dominant hypercholesterolemia.
    Varret M; Abifadel M; Rabès JP; Boileau C
    Clin Genet; 2008 Jan; 73(1):1-13. PubMed ID: 18028451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 in South African variants of familial hypercholesterolemia.
    Getz GS
    J Am Coll Cardiol; 2014 Jun; 63(22):2374-5. PubMed ID: 24632264
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD; Cohen JC; Hobbs HH
    Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PCSK9 - break through in the prevention and treatment of arteriosclerosis?].
    Lewartowski B
    Kardiol Pol; 2009 Jul; 67(7):782-6. PubMed ID: 19650002
    [No Abstract]   [Full Text] [Related]  

  • 30. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Santos RD; Watts GF
    Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
    [No Abstract]   [Full Text] [Related]  

  • 32. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
    Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
    J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
    Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
    J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
    Cunningham D; Danley DE; Geoghegan KF; Griffor MC; Hawkins JL; Subashi TA; Varghese AH; Ammirati MJ; Culp JS; Hoth LR; Mansour MN; McGrath KM; Seddon AP; Shenolikar S; Stutzman-Engwall KJ; Warren LC; Xia D; Qiu X
    Nat Struct Mol Biol; 2007 May; 14(5):413-9. PubMed ID: 17435765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
    Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
    Piper DE; Jackson S; Liu Q; Romanow WG; Shetterly S; Thibault ST; Shan B; Walker NP
    Structure; 2007 May; 15(5):545-52. PubMed ID: 17502100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia.
    Taylor A; Tabrah S; Wang D; Sozen M; Duxbury N; Whittall R; Humphries SE; Norbury G
    Clin Genet; 2007 Jun; 71(6):561-8. PubMed ID: 17539906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unravelling the functional significance of PCSK9.
    Lambert G
    Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 function and physiology.
    Peterson AS; Fong LG; Young SG
    J Lipid Res; 2008 Jun; 49(6):1152-6. PubMed ID: 18375913
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.